Articles tagged with: PAT-SM6
Press Releases»
- 4/12 patients (33%) showed evidence of stable disease; 2 patients for more than 130 days
- A clinically-relevant mean time to next therapy of 51 days
- PAT-SM6 specifically targets myeloma tumour cells in vivo and stimulates signifcant immune responses
- All dose levels administered were safe with no adverse events observed
- No evidence of immunogenicity; PK analysis showed PAT-SM6 to have a half-life of 7 hrs
Melbourne, Australia (Press Release) - Patrys Limited (ASX: PAB; “the Company”), a clinical stage biotechnology company, is pleased to announce the final results from …
Press Releases»
Melbourne, Australia (Press Release) - Patrys Limited (ASX:PAB), a clinical stage biotechnology company has today announced that it is initiating an investigator-sponsored trial (IST) evaluating the effectiveness of Patrys’ lead anti-cancer drug PAT-SM6 in combination with carfilzomib, in patients with relapsed and refractory multiple myeloma (MM). The trial will be headed by Professor Dr. Hermann Einsele, Director of the Department of Medicine II, University of Würzburg, Germany, and is being funded by Onyx Pharmaceuticals, Inc., an Amgen subsidiary.
Both clinical and preclinical studies of PAT-SM6 conducted to date have shown evidence of …
Press Releases»
- FDA grants orphan designation for PAT-SM6 in multiple myeloma
- Provides 7 years market exclusivity in the USA post approval
Melbourne, Australia (Press Release) - Patrys Limited (ASX: PAB), a clinical stage biotechnology company, has received confirmation of Orphan Medicinal Product Designation for its lead anti-cancer product PAT-SM6, from the USA Food and Drugs Administration (FDA).
PAT-SM6 has previously been granted orphan drug designation for multiple myeloma in Europe.
Orphan product designation is intended to provide incentives to encourage companies to pursue cures and treatments for rare diseases with high unmet …
Press Releases»
- Orphan designation confirmed for PAT-SM6 clinical product
- Provides 10 years market exclusivity in Europe post approval
- PAT-SM6 is active in multiple myeloma patients with end stage disease who are resistant to other marketed therapies
Melbourne, Australia (Press Release) - Patrys Limited (ASX: PAB), a clinical stage biotechnology company is pleased to announce that lead anti-cancer product PAT-SM6 has been granted orphan drug designation by the European Medicines Agency (EMA) for multiple myeloma.
Orphan drug status is awarded to drugs that offer potential therapeutic value in the treatment of rare diseases …
NewsFlash »
GF-15 May Prevent Myeloma Growth By Disrupting Cell Division – Results from a recent German preclinical study show that the compound GF–15 disrupts the division of myeloma cells and triggers their death. Specifically, GF–15 kills myeloma cells by preventing centrosomal clustering, a technique used by cancerous cells to divide correctly. The German researchers found that GF-15 was effective in 30 percent of bone marrow samples from relapsed myeloma patients. They also found that GF–15, in combination with melphalan (Alkeran), was significantly less toxic in mice than a GF-15 plus Velcade (bortezomib). The researchers conclude that their findings support further development of the drug in clinical trials. For more information, please see the study in Cancer Research (abstract).
Linsitinib May Help Overcome Velcade Resistance In Multiple Myeloma – A recent preclinical study found that the investigational treatment linsitinib (ASP7487, OSI-906), which is being developed Japanese pharmaceutical company Astellas Pharma, may help overcome Velcade resistance in multiple myeloma. Linsitinib is a protein that triggers cancer cell death by inhibiting insulin-like growth factor 1 (IGF-1). IGF-1 is found on the surface of human cells and has been linked to Velcade-resistance. Specifically, the researchers found that linsitinib acted synergistically with Velcade and killed 47 percent of Velcade-resistant myeloma cells. The investigators believe their findings provide a rationale for studying linsitinib together with Velcade in clinical trials. A Phase 1/2 trial of linsitinib in combination with Velcade and dexamethasone in relapsed and refractory multiple myeloma patients is starting at the University Health Network of Toronto (see related Beacon news). For more information, please see the study in the journal Blood (abstract).
Patrys To Start Phase 1/2 Trial Of PAT-SM6 In Relapsed/Refractory Myeloma – The Australian biopharmaceutical company Patrys announced last week that it will be starting a Phase 1/2 trial of its investigational drug PAT-SM6 in relapsed and refractory multiple myeloma patients in Germany. PAT-SM6 is a human antibody that has shown promising activity in preclinical studies in a variety of cancers, including melanoma, breast, colon and pancreatic cancer as well as multiple myeloma. The trial will start at the University Hospital of Wuerzbug, lead by myeloma expert Professor Herman Einsele. For more information, please the Patrys press release.
